NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Tenofovir Disoproxil Fumarate to Treat Pediatric HIV
- Conditions
- HIV Infection
- First Posted Date
- 2001-10-11
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00024986
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency
- Conditions
- IgA Deficiency
- First Posted Date
- 2001-10-10
- Last Posted Date
- 2016-09-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00024934
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Lamivudine and Adefovir to Treat Chronic Hepatitis B
- Conditions
- HBV (Hepatitis B Virus)Hepatitis BHepatitis
- Interventions
- First Posted Date
- 2001-09-03
- Last Posted Date
- 2016-09-23
- Target Recruit Count
- 41
- Registration Number
- NCT00023309
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Pegylated Interferon to Treat Chronic Hepatitis D
- Conditions
- Hepatitis D
- Interventions
- Drug: Peginterferon Alpha-2a
- First Posted Date
- 2001-09-03
- Last Posted Date
- 2013-07-10
- Target Recruit Count
- 13
- Registration Number
- NCT00023322
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 85
- Registration Number
- NCT00000652
- Locations
- 🇺🇸
Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
- Conditions
- Diffuse Large B-Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell LymphomaSmall Lymphocytic LymphomaFollicular Lymphoma
- Interventions
- Biological: ApolizumabBiological: Rituximab
- First Posted Date
- 2001-08-20
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00022971
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Gene Therapy for Patients With Leukocyte Adherence Deficiency (Follow-Up of Phase 1 Trial)
- Conditions
- Leukocyte Adhesion Deficiency Syndrome
- First Posted Date
- 2001-08-20
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2
- Registration Number
- NCT00023010
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Randomized Trial of Health Events Costs in Diabetic Blacks
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2001-08-10
- Last Posted Date
- 2010-01-15
- Target Recruit Count
- 800
- Registration Number
- NCT00022750
- Locations
- 🇺🇸
The Johns Hopkins Medical Institutions, Baltimore, Maryland, United States
PTHrP and Osteoporosis
- Conditions
- Osteoporosis
- Locations
- 🇺🇸
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
Islet Cell Transplantation Alone in Patients With Type I Diabetes Mellitus: Steroid-free Immunosuppression
- Conditions
- Diabetes Mellitus, Type 1
- Locations
- 🇺🇸
University of Miami Diabetes Research Institute, Miami, Florida, United States